(Q38336384)

2 September 2017

title

Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer (English)

1 reference

2 September 2017

1 reference

William C Zamboni

1

1 reference

2 September 2017

Austin J Combest

2

1 reference

2 September 2017

Julie A DeLoia

3

1 reference

2 September 2017

Robert P Edwards

4

1 reference

2 September 2017

Arlene S Bridges

5

1 reference

2 September 2017

Beth A Zamboni

6

1 reference

2 September 2017

Christine M Walko

7

1 reference

2 September 2017

Angela Y C Yu

8

1 reference

2 September 2017

Thomas C Krivak

9

1 reference

2 September 2017

Joseph L Kelley

10

1 reference

2 September 2017

language of work or name

1 reference

25 March 2011

1 reference

Cancer Chemotherapy and Pharmacology

2 September 2017

published in

1 reference

2 September 2017

volume

68

1 reference

2 September 2017

issue

5

1 reference

2 September 2017

page(s)

1255-1262

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-011-1609-9

2 September 2017

exact match

0 references

cites work

Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: active combination with low incidence of peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

Pharmacogenetic pathway analysis of docetaxel elimination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

Simple and rapid docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

Quantitation of midazolam in human plasma by automated chip-based infusion nanoelectrospray tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

The prognostic value of post chemotherapy serum CA 125 in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1609-9

10.1007/S00280-011-1609-9

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

2 September 2017

1003408917

0 references

1 reference